S. Korea to approve Viagra generics

Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday.

The Korea said generic products made by the three local firms have passed a "bioequivalence" test.

"The three firms are expected to get approval for production of Viagra generics probably this month or later," an official in charge of medicine tests told AFP on condition of anonymity.

"Our move has nothing to do with an ongoing patent row," he said, adding the watchdog is also expected to give the go ahead for more local firms.

Numerous domestic pharmaceutical firms have applied for approval to manufacture Viagra generics since it was introduced in in 1999.

US pharmaceutical giant Pfizer claims its patent, which involves using sildenafil, is valid until May 2014.

"Our patent covering the material is still valid," a Pfizer official in Seoul said, urging South Korean firms to recognise it.

Pfizer has yet to counter a lawsuit filed by CJ Cheiljedang, a domestic seeking to invalidate the patent.

"We plan to produce a generic Viagra regardless of the court's ruling, even if we have to compensate Pfizer in the future," an unnamed CJ Cheiljedang official told Yonhap news agency.

add to favorites email to friend print save as pdf

Related Stories

Drug firm GSK fined $2.6 million for collusion

Oct 24, 2011

South Korea's anti-trust agency has fined drugmaker GlaxoSmithKline three billion won ($2.6 million) for conspiring with a Seoul rival over the sale of drugs, an official said Monday.

Slovenia to launch generic version of Viagra

Jul 31, 2009

Krka, the biggest drugmaker in Slovenia, said Friday that its generic version of the impotency drug Viagra would be launched in September and priced 30 percent cheaper than the original.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments